Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT6 | P42226 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 9/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | SYK | P43405 | 3/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19010277 | 0.94 | KMT2A (0.44) | STAT6MAPTKMT2ASMN1; SMN2MAPK1 | |
| SCHEMBL17021291 | 0.93 | STAT6 (0.49) | STAT6MAPTKMT2ASMN1; SMN2MAPK1 | |
| SCHEMBL19010264 | 0.91 | MAPT (0.42) | STAT6MAPTKMT2ASMN1; SMN2MAPK1 | |
| SCHEMBL19010285 | 0.88 | STAT6 (0.56) | STAT6MAPTKMT2AMAPK1GAA | |
| SCHEMBL19010267 | 0.88 | STAT6 (0.45) | STAT6MAPTKMT2ASMN1; SMN2MAPK1 | |
| SCHEMBL19010268 | 0.86 | JAK3 (0.46) | STAT6MAPTKMT2ASMN1; SMN2MAPK1 | |
| SCHEMBL17021296 | 0.86 | STAT6 (0.47) | STAT6MAPTKMT2ASMN1; SMN2MAPK1 | |
| SCHEMBL19010274 | 0.86 | GFER (0.49) | STAT6MAPTKMT2ASMN1; SMN2MAPK1 | |
| SCHEMBL19010266 | 0.85 | MAPT (0.45) | STAT6MAPTKMT2ASMN1; SMN2MAPK1 | |
| SCHEMBL17021325 | 0.84 | STAT6 (0.47) | STAT6MAPTKMT2ASMN1; SMN2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9834548-B2 | Pyridazine compounds as JAK inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-20170174673-A1 | PYRIDAZINE COMPOUNDS AS JAK INHIBITORS | ALEXION PHARMACEUTICALS, INC. | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174673-A1 | PYRIDAZINE COMPOUNDS AS JAK INHIBITORS | JAK1, JAK2, JAK3 | STAT6 8/4885MAPT 53/4885KMT2A 1060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.